Table 4.

Incidence of Kidney Injury in Selected High‐Risk Individuals by Treatment Arm in A‐to‐Z

Subgroup	Rise in sCr With Baseline sCr as Referent	Simvastatin 40/80 mg QD	Placebo/Simva 20 mg QD	P Value
Diabetic patients (n=994)	≥1.5‐fold or ≥0.3‐mg/dL rise	12.6%	15.0%	0.29
	≥1.5‐fold	2.20%	3.03%	0.42
	≥2.0‐fold	0.40%	0.81%	0.45
	≥3.0‐fold or sCr ≥4.0 mg/dL	0.40%	0.40%	1.00
Baseline eGFR <60 mL/min per 1.73 m2 (n=2554)	≥1.5‐fold or ≥0.3‐mg/dL rise	10.1%	9.8%	0.80
	≥1.5‐fold	1.25%	1.97%	0.15
	≥2.0‐fold	0.31%	0.24%	1.00
	≥3.0‐fold or sCr ≥4.0 mg/dL	0.23%	0.08%	0.63

eGFR indicates estimated glomerular filtration rate; sCr, serum creatinine.